喜讯 | Renata公司莅临我司开展原料药现场审计，合作信心再添强援
Great News | Renata Company Conducts On-Site Audit of APIs at Our Company, Further Strengthening Confidence in Cooperation
2025年10月21日，孟加拉国知名制药企业Renata有限公司（以下简称“Renata公司”）审计团队一行，莅临我司就原料药生产与质量管理体系开展专项现场审计。该公司目前已有多个吸入制剂用 API 与我司建立了合作，作为孟加拉国制药行业的领军企业，Renata公司在全球医药市场拥有广泛的影响力与严格的供应商准入标准。此次现场审计，其团队依据GMP及自身核心采购标准，对我司进行了全链条、多维度的细致核查。审计范围涵盖原料药生产车间的设施设备运行状况、生产工艺流程的规范性、原辅料及成品的检验检测、质量追溯系统的完整性、仓储物流的合规管理，以及数据完整性等关键环节。经过为期一天的严谨核查与深度交流，审计团队对我司在生产合规性、质量管理能力及供应链保障等方面的表现给予高度评价与认可，为双方深化战略合作奠定了坚实基础。
On October 21, 2025, an audit team from Renata Limited ("Renata" for short), a renowned pharmaceutical enterprise in Bangladesh, visited our company to conduct a special on-site audit on the production and quality management system of APIs. Currently, the company has established cooperation with us on multiple APIs for inhalation formulations. As a leading enterprise in Bangladesh's pharmaceutical industry, Renata enjoys extensive influence in the global pharmaceutical market and maintains stringent supplier access standards. During this on-site audit, the team conducted a full-chain, multi-dimensional and meticulous verification of our company in accordance with GMP and its own core procurement criteria. The audit scope covered key links including the operation status of facilities and equipment in API production workshops, the standardization of production processes, the inspection and testing of raw materials, auxiliary materials and finished products, the integrity of the quality traceability system, the compliant management of warehousing and logistics, as well as data integrity. After a full day of rigorous verification and in-depth communication, the audit team highly recognized and praised our company's performance in production compliance, quality management capabilities and supply chain security, laying a solid foundation for the deepening of strategic cooperation between the two parties.
我司也将以此为新起点，持续深耕医药领域，坚守质量底线，强化创新驱动，为全球医药健康事业的发展贡献坚实力量。
Taking this as a new starting point, our company will continue to deepen its presence in the pharmaceutical field, uphold the bottom line of quality, strengthen innovation-driven development, and contribute solid strength to the progress of the global pharmaceutical and healthcare industry.